The latest price trend and purchasing reference information of amivantamab in 2025

Amivantamab (also known as Rybrevant) is a drug manufactured by Johnson & Johnson (Johnson & The EGFR/MET bispecific antibody drug developed by Johnson is specifically used to treat patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations. In February this year, the drug was officially approved for marketing in China. Although it has not yet been included in medical insurance, the domestic market supply is still in its early stages, so patients may have difficulty purchasing it directly in hospital pharmacies.

At present, the official pricing of evantumumab in the domestic market has not been widely disclosed, but with reference to the price in Hong Kong, its original research version of 350mg specifications (such as Rybr evant® () is priced at approximately 14,340 Hong Kong dollars, which is equivalent to approximately 1 yuan in RMB. Since Hong Kong's market supply is relatively mature, many patients choose to purchase drugs through Hong Kong's formal channels to cope with domestic supply shortages.

Looking at global price trends, evantumumab is still a high-priced anti-cancer drug. A cost-effectiveness evaluation in Chinese economic research shows that compared with osimertinib, the high treatment cost of this drug makes it not yet cost-effective within the current medical insurance payment scope . This means that if the drug is included in medical insurance or generic drugs are introduced in the future, drug prices may drop significantly.

Taken together, evantumumab will still be in a high-value and high-price stage in2025. When considering medication, patients should weigh its clinical efficacy and economic affordability. Currently, the available purchasing channels include waiting for introduction by domestic hospitals and purchasing the original version in Hong Kong. The price is approximately RMB 10,000 per unit. In the future, as domestic promotion accelerates, medical insurance negotiations advance, or generic drugs are launched, the drug's accessibility and price are expected to further improve.

Reference: https://go.drugbank.com/drugs/